The cell therapy market involves therapeutic cells that are utilized to treat diseases, organ failures and other damaged tissues. Cell therapies use human cells to improve damage or disease in the body. They work by stimulating and enhancing the body's natural healing response through transplantation and injection. Major types of cell therapies include stem cell therapy, immune cell therapy and others. The increasing prevalence of chronic diseases such as cancer, cardiac disorders and neurological disorders has increased the demand for cell therapies globally.



The Global cell therapy market is estimated to be valued at US$ 1921.74 Mn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024 to 2031.

The rising chronic disease prevalence and increased funding for R&D are major factors driving the growth of this market.



Key Takeaways



Key players operating in the cell therapy market are Archer Daniels Midland Company, Kemin Industries, International Flavors Fragrances Inc., Aquanova AG, Ajinomoto Co. Inc., Penta International Corp, Chr., Hansen A/S, Biolink Group, Indena SpA, Symrise AG, and Van Drunen Farms. These key players are actively investing in R&D to develop advanced cell therapies.



The major opportunities in the Cell Therapy Market Insights include new product approvals and launch of advanced therapies for wider applications. Recently, the FDA approved the first CAR T-cell therapy for the treatment of multiple myeloma. Such new product approvals are creating significant opportunities in this market.



Further, the key players are focusing on global expansion through collaborations and acquisitions. For instance, in 2022, Kadimastem acquired South Korean biopharma MediPost to expand its presence in Asia Pacific. Such strategic initiatives are helping players strengthen their geographic footprint.



Market Drivers



The increasing prevalence of chronic diseases globally is a major driver augmenting the demand for cell therapies. Chronic diseases such as cancer, cardiovascular diseases and neurological disorders pose a major economic and social burden. According to WHO, cancer burden is expected to grow to 27 million new cancer cases per year by 2040. This rising disease incidence is anticipated to significantly drive the cell therapy market during the forecast period.



Market Restraints



High costs associated with cell therapy manufacturing and storage are a major restraint hampering the market growth. Cell therapies require specialized facilities, expensive materials and trained workforce which increases the overall costs. Further, regulatory issues pertaining to safety and efficacy also challenge the widespread adoption of new cell therapies. Stringent regulations delay the launch of new products which negatively impacts the market revenues.

Segment Analysis



Allogeneic Cell Therapy Market Regional Analysis dominates the cell therapy market currently owing to its ease of availability and cost-effectiveness compared to autologous cell therapy. Allogeneic cell therapies are derived from tissues unrelated from the patient. This reduces therapy preparation time and associated costs compared to autologous therapy. Off-the-shelf availability of allogeneic cell therapies also provides a significant advantage as they can reach patients faster without requiring custom preparation for each patient. While autologous cell therapy poses lower immunological risks, the complex customization process increases therapy costs and delays treatment. This factor has supported the higher market share of allogeneic cell therapy currently.



Global Analysis



The North American region currently dominates the global cell therapy market owing to presence of established healthcare infrastructure, favorable reimbursement policies, high adoption of advanced therapies, and major market players in the region. The presence of leading research institutes and increasing funding for cell-based research further support market growth. However, the Asia Pacific region is anticipated to witness the highest growth during the forecast period due to increasing government support for healthcare development, rising disposable incomes, growing medical tourism industry and rapid expansion of healthcare infrastructure in emerging countries. The increasing aging population and disease incidences also present lucrative growth opportunities for cell therapy in Asia Pacific.

For More Insights Discover the Report In language that Resonates with you

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)